CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>60%
Status:
Not yet recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
Limiting brain death-induced organ injury through a systemic anti- inflammatory medical
management should allow for improvement in the quality of transplanted organs, and as a
result, clinical improvement in post-transplant outcomes represented by a decrease in the
incidence of delayed graft function (DGF) after transplantation.
The specific aim is to evaluate the effect of C1INH (CINRYZE) as a donor pre-treatment
strategy to decrease systemic inflammation and decrease the incidence of DGF in Expanded
Criteria Donors (ECD), currently identified as donors with Kidney Donor Profile Index (KDPI)
greater than or equal to 60%.